Skip to main content

Recent News

  • Feb 26, 2024
    Behcets_disease.jpg

    A comprehensive overview of Behcet's syndrome appeared in last week's NEJM, reviewing the numerous advances in the immunogenetics, syndrome recognition, and targeted therapeutic approaches. Despite certain advances, there remains a need for better clinical trials, better diagnostic tools, and biologic treatments to afford better outcomes. 

    Read Article
JAKi Safety and Efficacy in bDMARD-IR Patients With RA This ACR 2023 poster shows SELECT-CHOICE outcomes through Week 204 from bDMARD-IR patients with RA, including TNFi-IR subgroup outcomes. Sponsored by AbbVie US Medical Affairs. https://t.co/OOZOSb9Bye https://t.co/tA4wCAWOS8
Dr. John Cush @RheumNow (  View Tweet)
Feb 27, 2024
Immunosuppression Increasing Dr. Jack Cush reviews the news and journal reports from the past 2 weeks on https://t.co/V10S4oVFsv; but begins with a discussion of what constitutes "immunosuppression" and how it applies to our patients. https://t.co/KvZIiKowox https://t.co/cbBYydVQbB
Dr. John Cush @RheumNow (  View Tweet)
Feb 27, 2024
Experts and patient discuss ear, nose, and throat manifestations in severe active granulomatosis with polyangiitis. This therapeutic update is sponsored by Amgen US Medical Affairs. https://t.co/LPiw3ztZQw

Dr. John Cush @RheumNow (  View Tweet)

Feb 27, 2024
Single center study of 163 pts (mostly RA) Rx w/ tocilizumab found 41 hospitalized & 49% for serious infx. SIE were more common w/ eosinopenia (EC < 0.05 g/L; avg (0.06 vs 0.20 g/L) & low ratio EC/NC ratio (× 1000 < 11.8) (median (6.54 vs 48.50). https://t.co/88sbHBIhXt https://t.co/6wUeqSbVxx
Dr. John Cush @RheumNow (  View Tweet)
Feb 27, 2024

EGPA: Benralizumab or Mepolizumab

Feb 26, 2024

A multicenter, double-blind, phase 3, randomized, active-controlled trial has shown that Benralizumab (BEN) was noninferior to mepolizumab (MEP) for the induction of remission of patients with relapsing or refractory Eosinophilic granulomatosis with polyangiitis (EGPA).

Read Article
No clear link between weather & MSK symptoms There is a belief that changes in weather conditions, such as impending rain or temperature, can trigger or worsen muscle and joint pain but Australian researchers have found no clear pattern between the two. https://t.co/V3rfCTWRBQ https://t.co/eFdZH4LoNA
Dr. John Cush @RheumNow (  View Tweet)
Feb 26, 2024
CD19 CAR T-Cell Therapy in Autoimmune Disease The NEJM has published the results of CD19 B cell depletion (by CAR-T cell therapy) in autoimmune disease patients, demonstrating it to be feasible, safe, and efficacious. https://t.co/ym3pAsI5Sf https://t.co/AnfKOISscV
Dr. John Cush @RheumNow (  View Tweet)
Feb 26, 2024
RA BIOBADASER registry study of 1128 patients going on ts/bDMARD found 107 (9.3%) w/ multimorbidity (Charlson Comorbidity index ≥ 3). Multimorbid RA were older, more SJC & signif higher DAS28; ts/bDMARD retention rate equal groups https://t.co/am4Uoccla9 https://t.co/P7Ae2Jal2e
Dr. John Cush @RheumNow (  View Tweet)
Feb 26, 2024
Feb 2024 EMA meeting approved biosimilar ustekinumab (Pyzchiva) for adult/pediatric psoriasis; psoriatic arthritis; UC/Crohn's. & also approved generic Apremilast Accordfor the treatment of psoriatic arthritis, psoriasis, and Behçet disease https://t.co/Cu9f4qQjgP https://t.co/qmH3ZkfReN
Dr. John Cush @RheumNow (  View Tweet)
Feb 26, 2024
Congratulations to Drs. David Felson Tuhina Neogi of Boston University in being awarded a U19 5 yr grant to fund Novel Insights into Osteoarthritis, Pain and Function: The Multicenter Osteoarthritis (MOST) Study. https://t.co/fGU9Zk2ECs https://t.co/dtT0hu7aA1
Dr. John Cush @RheumNow (  View Tweet)
Feb 26, 2024
MMPs play pathogenic role in RA-ILD. Multicenter VA study of 2,312 RA pts, 96 had prevalent ILD & Incident ILD developed in 130 (IR 7.5/1,000PY). High MMP-7 increased ILD (adj OR 3.78) & incident ILD (adj HR 2.33). Higher MMP-9 did same https://t.co/3i49TsAQbt https://t.co/RA6Fu2jPeE
Dr. John Cush @RheumNow (  View Tweet)
Feb 26, 2024
Eating for RA The majority of practicing rheums at RheumNow Live were unaware of the new ACR guidelines issued in 2022 regarding dietary and lifestyle recommendations for patients with RA. Dr. Monica Guma reviewed these guidelines during her lecture. https://t.co/9herN2musx https://t.co/P1xJn2lDrg
Dr. John Cush @RheumNow (  View Tweet)
Feb 26, 2024
Serial plasma samples assayed for 92 inflammation-related proteins, during and after gout attacks. 21 were differentially expressed. Gout flares assoc w/ increased IL-6, CSF-1, VEGF-A & tumour necrosis factor superfamily 14 (TNFSF14 was highest) https://t.co/2p8vTFcmvD https://t.co/5z1gYdsKJO
Dr. John Cush @RheumNow (  View Tweet)
Feb 25, 2024
Week 52 outcomes of 180 lupus nephritis pts (IV, VI, III) from AMP academic centers (rx w/ standard of care) showed 22% complete resp,  22% partial resp, 42% non-responder& 14% undetermined. 8/180 (4.4%) had CR sustained Wk 12 to 52; 10% PR. An unmet need! https://t.co/MJklf0Xhih https://t.co/w6a1fLKmoF
Dr. John Cush @RheumNow (  View Tweet)
Feb 25, 2024
Cochrane Review: How Good is Ultrasound Diagnosing GCA? Is temporal artery ultrasound (US) equivalent or superior to the reference standard of temporal artery biopsy (TAB) when diagnosing giant cell arteritis (GCA)? https://t.co/AcETp0TJBF https://t.co/eKVmaro7D0
Dr. John Cush @RheumNow (  View Tweet)
Feb 25, 2024
Vasculitis Pearls Once again RheumNow Live 2024 really delivered with high impact learning packed into short sessions. As someone with an interest in vasculitis it was fantastic to see four of my favorite speakers in the Vasculitis Mavens and STEP talks https://t.co/Oee5nRhTAx https://t.co/sJGwCzLUQq
Dr. John Cush @RheumNow (  View Tweet)
Feb 25, 2024
How do you manage enthesitis? Enthesitis can be a challenge for clinicians to identify, evaluate, and manage in patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). https://t.co/BlC3onBYSX https://t.co/OXPdZuJHaN
Dr. John Cush @RheumNow (  View Tweet)
Feb 24, 2024
Long-Term, open-label study enrolled EGPA (MIRRA study) required prednisolone ≥5 mg/d, pts cont mepolizumab 300 mg Sc q 4 wks +SOC. 100 pts - 71% completed, 3% d/C due to AEs. Exposure~38 mos; 38% serious AEs (30/100PYs) (worsening of asthma, EGPA https://t.co/GKxXN8p2Wz https://t.co/TFd9s3tfjK
Dr. John Cush @RheumNow (  View Tweet)
Feb 24, 2024
Top 5 Clinical Pearls in RA Management #RNL2024 provided a wealth of clinical insights, particularly in the realm of rheumatoid arthritis (RA) management. Here are the top five clinical pearls from the event's opening session, "Success in RA." https://t.co/DUalEZbfJB https://t.co/RZsW0SKc4J
Dr. John Cush @RheumNow (  View Tweet)
Feb 24, 2024
Five Takeaways in PsA/SpA at RNL 2024 Continuing with the theme of clinical pearls, the PsA and SpA speakers also provided a wealth of information. Click the link to read our five key takeaways and clinical pearls. https://t.co/ekKUl5WelF https://t.co/IdPXd7LR65
Dr. John Cush @RheumNow (  View Tweet)
Feb 23, 2024